- Ozempic butt.
- Ozempic tongue.
- Ozempic fingers.
- Ozempic burps.
- Ozempic dreams.
- Ozempic diarrhea.
- Ozempic hair.
The list of side effects from glucagon-like peptide-1 (GLP-1) agonists Ozempic/Wegovy, and Mounjaro/Zepbound seems to expand over time in inverse proportion to the waistlines, fingers, and butts of those who take them, as shown in the “Ozem-pics” above.
A new class of better tolerated therapies called NLRP3 inflammasome inhibitors may one day compete with GLP-1 agonists for the treatment of obesity.
This is based on a provocatively interesting presentation from the biopharmaceutical company, Ventyx Biosciences (link here). Ventyx Bio’s NLRP3 inflammasome inhibitor called VTX3232 decreased food consumption, body weight, liver steatosis, cholesterolemia, insulin resistance, and systemic inflammatory biomarkers including IL-1β, IL-6, and fibrinogen in diet-induced obesity (DIO) mice both alone and in combination with the GLP-1 receptor agonist, semaglutide (Ozempic) vs. DIO (high fat diet) controls.
We call these results food for thought.